28 Mar 2024
Sunday 6 March 2016 - 13:34
Story Code : 204874

Fighting the Flu: Russia and Iran team up to defeat Influenza

The Russian developers of the 'Grippol Plus' flu vaccine have agreed on a partnership with Iranian counterparts who will localize production of the vaccine in Iran.

Russian pharmaceutical firm Petrovax and two Iranian manufacturers have signed an agreement tolocalize the production ofthe 'Grippol Plus' influenza vaccine inIran.

The 'Grippol Plus' vaccine is given tochildren and pregnant women toprevent them falling ill withflu, and is sold throughoutthe Commonwealth ofIndependent States and insome EU countries, forexample Slovakia.

After extensive testing inthe Islamic Republic, doctors there decided that the vaccine would be a welcome addition totheir medical arsenal, and Iranian manufacturers ofpharmaceuticals asked Petrovax forthe right toproduce the vaccine, Petrovax President Yelena Arhangelskaya told Sputnik.

"We made the first delivery of 'Grippol Plus' toIran in2015 and got positive reviews fromIran's Ministry ofHealth and the relevant medical specialists. After that we got an offer fromIranian company Sobhan Recombinant Protein forthe transfer oftechnology toproduce 'Grippol Plus.'"
"This is a new strategic direction forPetrovax Pharm, and strengthens our export potential. The importance forIran is obvious atthe moment there are no locally-produced vaccines there."

"We accepted the offer, and according tothe terms ofour agreement overthe next three years there will be a gradual transfer oftechnology acrossthe production cycle ofthe vaccine," Arhangelskaya explained.

"This allows Iran toincrease the number ofpeople who are vaccinated and gives the opportunity toadd the vaccine tothe national immunization program, asis practiced inmany countries."

Arhangelskaya said that Iranian experts fromSRP will be inconsultation withtheir colleagues fromPetrovax atevery stage ofthe localization process, afterwhich the medicine must receive approval fromIran's Health Ministry beforeit goes onthe market.

She also revealed that Petrovax has signed another two agreements withSRP and another Iranian pharmaceutical company, according towhich the Iranian manufacturers will help Petrovax toproduce treatments forhepatitis and rheumatoid arthritis.
"SRP will transfer the technology toproduce a hepatitis B vaccine inRussia, and so Petrovax will complete a similar process toacquire the production technology," Arhangelskaya said.


"Another agreement has been signed withCinnaGen totransfer the technology toproduce and license drugs totreat rheumatoid arthritis. This company has a wide range ofmedicine and if our first project proves successful we will definitely expand our cooperation."
By Sputnik
https://theiranproject.com/vdcefe8wejh87vi.1kbj.html
Your Name
Your Email Address